Biovaxys Technol Stock Price, News & Analysis

BioVaxys Technology Corp. (OTCQB: BVAXF) has announced a 10:1 share consolidation of its common shares, expected to commence trading on September 11, 2025. Following the consolidation, the company's outstanding shares will reduce from 293,425,203 to approximately 29,342,496 shares.

The consolidation will adjust the exercise price and number of shares for outstanding convertible securities proportionally, except for Debenture Warrants. Registered shareholders with physical certificates must submit them along with a transmittal letter to Odyssey Trust Company, while shareholders without physical certificates need not take action.

BioVaxys is a clinical-stage biopharmaceutical company developing immunotherapies, including its DPX™ platform and HapTenix© tumor cell construct platform for treating cancers and other immunological diseases.

BioVaxys Technology Corp. provided a comprehensive corporate update on its operations and strategic initiatives. The company is focusing on integrating assets acquired from IMV Inc. in February 2024, including the DPX immune educating platform. Key developments include out-licensing DPX technology, restarting clinical studies (notably DPX-surMAGE for bladder cancer), and reducing risk through amended milestone provisions with Horizon Technology Finance. BioVaxys is pursuing multiple pipeline expansions through collaborations, including partnerships with AP Visionaries for food allergy treatments and Sona Nanotech for cancer therapeutics. The company's late-stage pipeline includes MVP-S in phase 2b for lymphoma and ovarian cancer, showing promising clinical results. BioVaxys announced a 10:1 share consolidation and is pursuing a private placement to raise between $2-3 million.

BioVaxys Technology Corp has executed an amendment to its Asset Purchase Agreement (APA) with Horizon Technology Finance Corporation regarding the acquisition of IMV Inc's DPX immune educating platform technology assets. The key changes include: 1) Reduction of the performance milestone from USD $10M to USD $2.03M, to be raised by September 30, 2025; 2) Extension of the Licensing Earn-Out Payments Term to August 11, 2033; 3) Issuance of 2.8M warrants to Horizon and 1.2M warrants to Powerscourt at CAD $0.06 per share, exercisable until May 31, 2028. The amendment modifies terms for capital raising requirements and revenue sharing arrangements from licensing agreements.

BioVaxys Technology Corp. (BVAXF) and Sona Nanotech Inc. have entered into a Research Agreement to develop new cancer therapeutics. The collaboration combines BioVaxys' DPX™ Immune Educating Platform with Sona's Targeted Hyperthermia Therapy™ (THT) and Gold Nanorod technology. The research will be conducted at Dalhousie University, evaluating DPX's immune stimulatory properties when used with THT, and exploring DPX as a carrier for novel neoantigens expressed after immunotherapy. In preclinical studies, Sona's THT demonstrated a 100% response rate in immunotherapy-resistant tumors when combined with PD-1 inhibition. The collaboration costs will be covered by the Giacomantonio Immuno-Oncology Research Group, with both companies co-owning any developed therapeutics.

BioVaxys Technology Corp. (BVAXF) and SpayVac for Wildlife have expanded their License Agreement to include commercial aquaculture and farm-raised fish markets. The expansion targets a significant market opportunity in farm-raised Atlantic salmon and rainbow trout, with an annual harvest of approximately 3.28 million metric tons (800 million individual fish).

SpayVac's single-dose fertility-control vaccines offer an alternative to triploidy in aquaculture, with initial proof-of-concept trials progressing to the second phase. The technology uses a patented liposome-based delivery platform, demonstrating 4-10 years of contraceptive efficacy in various species.

The company is pursuing regulatory approval for feral horses and free-ranging deer populations, with the U.S. Bureau of Land Management (BLM) as a potential lead customer. The BLM currently manages 53,797 horses on the range, significantly above the Appropriate Management Level of 22,637, spending 66% of its $153 million budget on long-term holding costs.

BioVaxys Technology Corp (BVAXF) is developing its DPX™ platform as an alternative to lipid nanoparticles (LNPs) for delivering mRNA vaccines. The DPX technology is a patented delivery platform that can incorporate various bioactive molecules to produce targeted, long-lasting immune responses.

Proof-of-concept studies conducted with Etherna and PCI Biotech showed that DPX provides enhanced stability of packaged mRNA, attracts specific Antigen Presenting Cells to the injection site, and induces specific immune responses. Unlike LNPs, which can cause adverse reactions and stability issues, DPX remains localized at the injection site and demonstrated stability for up to 14 days in vivo.

The company is pursuing collaborations with organizations having promising tumor and virus-specific polynucleotide antigens, positioning DPX as a potential solution in the mRNA vaccine market, which is projected to reach $48 billion by 2030.

BioVaxys Technology Corp. (CSE: BIOV, OTCQB: BVAXF) has announced its upcoming presentation at the Emerging Growth Conference on Thursday, January 16, 2025, from 3:25 PM to 3:35 PM Eastern Time. The clinical-stage company, which develops vaccines using its DPX™ immune educating platform for cancers, infectious diseases, and immune disorders, will host an interactive online session.

CEO James Passin and President & COO Kenneth Kovan will lead the presentation, offering shareholders and investors a real-time interaction opportunity. The event includes a Q&A session, with questions accepted both in advance via Questions@EmergingGrowth.com and during the live presentation. Participants who cannot attend live can access an archived webcast through EmergingGrowth.com and their YouTube channel.

BioVaxys Technology Corp (CSE: BIOV, OTCQB: BVAXF) has secured a 48-kilogram supply of GMP-grade lipid for its DPX antigen packaging delivery platform. The lipids, previously owned by IMV Inc., will be used to restart clinical studies and initiate new preclinical studies. The company acquired IMV's intellectual property and programs in February 2024.

The DPX technology is a patented delivery platform capable of packaging various bioactive molecules, including mRNA, peptides, proteins, and small molecules. This non-aqueous and non-systemic platform enables immune cell recruitment and antigen uptake at injection sites, delivering to regional lymph nodes via Antigen Presenting Cells to stimulate durable immune responses.

BioVaxys Technology Corp. and SpayVac for Wildlife announce that SpayVac's Madison facility is now fully operational to produce two contraceptive vaccines: the pZP vaccine (SpayVac®) and a new GnRH vaccine for aquaculture. The scaled-up production capacity will support field trials, market studies, and new antigen formulations. Recent large-scale shipments were made for a feral horse project in Europe and an immunocontraception project in Southeast Asia. The company is conducting trials with the U.S. government, EU, and an aquaculture genetics company, exploring alternatives to induced triploidy. SpayVac's technology, licensed from BioVaxys, uses a patented liposome-based antigen delivery platform.